Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-332,860
Closed -$21.7M 85
2025
Q4
$21.7M Buy
332,860
+321,484
+2,826% +$25.6M 3.72% 6
2025
Q3
$934K Sell
11,376
-190,076
-94% -$13.7M 0.19% 62
2025
Q2
$13.3M Sell
201,452
-72,322
-26% -$4.5M 4.26% 7
2025
Q1
$18M Buy
+273,774
New +$18.5M 5.73% 4
2024
Q4
Sell
-60,076
Closed -$5.02M 55
2024
Q3
$5.02M Sell
60,076
-220,633
-79% -$14.7M 1.5% 21
2024
Q2
$15.5M Buy
280,709
+140,442
+100% +$7.63M 4.55% 6
2024
Q1
$9.76M Sell
140,267
-173,337
-55% -$11M 2.58% 13
2023
Q4
$17.4M Buy
+313,604
New +$14.1M 4.64% 3

Other funds holding ACLX

Stempoint Capital's ACLX Position: Q1 2026 in Review

Stempoint Capital sold out of Arcellx (ACLX) in Q1 2026, closing a stake of 332,860 shares — an estimated $21.7M sold.

Stempoint Capital first reported a position in ACLX in Q4 2023 and held it in 8 quarters. The position peaked at $21.7M in Q4 2025. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

  • Stempoint Capital reported no remaining Arcellx position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 332,860 Arcellx shares in Q1 2026, an estimated $21.7M.
  • Stempoint Capital first reported a position in Arcellx in Q4 2023 and held it in 8 quarters.
  • Stempoint Capital's Arcellx position peaked at $21.7M in Q4 2025.
  • 239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.